Bristol-Myers Squibb (BMY) Declares $0.49 Quarterly Dividend; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Bristol-Myers Squibb (BMY) CheckMate-743 Phase 3 Trial Data Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma
September 13, 2021 7:00 AM EDTBristol Myers Squibb (NYSE: BMY) today announced three-year data from the CheckMate -743 trial that demonstrated a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to platinum-based standard-of-care chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM), regardless of histology.
With a minimum follow-up of three years (35.5... More
Bolt Technology Corp. (BOLT) Collaborates with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors
September 8, 2021 7:31 AM EDTBolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to investigate Bolt Biotherapeutics BDC-1001 in combination with Bristol Myers Squibbs PD-1 checkpoint inhibitor Opdivo® (nivolumab). BDC-1001 is a HER2-targeting Boltbody immune-stimulating antibody conjugate (ISAC) in development for the treatment of patients with... More
Bristol-Myers Squibb Co. (BMY) PT Raised to $85 at Societe Generale
September 7, 2021 4:58 AM EDTSociete Generale analyst Justin Smith raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $85.00 (from $80.00) while maintaining a Buy rating.... More
